ARS Pharmaceuticals Falls After Wider-Than-Expected 1Q Loss

Dow Jones

May 15, 2025

By Chris Wack

Shares of ARS Pharmaceuticals slipped after the biopharmaceutical company reported a first-quarter loss that was wider than analysts had expected.

The stock was down 9%, to $12.12, in midday trading Wednesday, but has gained about 14% since the start of the year.

The San Diego company reported a first-quarter loss of $34.1 million, or 35 cents a share. Analysts polled by FactSet were looking for a loss of $31.2 million, or 34 cents a share.

Revenue for the quarter was $8 million, compared with the $7.5 million analysts were expecting.

Product revenue from its neffy sales in the U.S. were $7.8 million, and $200,000 in revenue came from a collaboration with Denmark's ALK-Abello. Neffy is a nasal spray used for emergency treatment of allergic reactions, including anaphylaxis.

ARS said it had cash, cash equivalents and short-term investments of $275.7 million as of March 31.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

May 14, 2025 12:51 ET (16:51 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2535008648"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2535008648\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2535008648?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-15 00:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2535008648","market":"hk","top_or_hot":-1,"title":"ARS Pharmaceuticals Falls After Wider-Than-Expected 1Q Loss","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Chris Wack \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of ARS Pharmaceuticals slipped after the biopharmaceutical company reported a first-quarter loss that was wider than analysts had expected. \n</p>\n<p>\n  The stock was down 9%, to $12.12, in midday trading Wednesday, but has gained about 14% since the start of the year. \n</p>\n<p>\n  The San Diego company reported a first-quarter loss of $34.1 million, or 35 cents a share. Analysts polled by FactSet were looking for a loss of $31.2 million, or 34 cents a share. \n</p>\n<p>\n  Revenue for the quarter was $8 million, compared with the $7.5 million analysts were expecting. \n</p>\n<p>\n  Product revenue from its neffy sales in the U.S. were $7.8 million, and $200,000 in revenue came from a collaboration with Denmark's ALK-Abello. Neffy is a nasal spray used for emergency treatment of allergic reactions, including anaphylaxis. \n</p>\n<p>\n  ARS said it had cash, cash equivalents and short-term investments of $275.7 million as of March 31. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Chris Wack at chris.wack@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 14, 2025 12:51 ET (16:51 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ARS Pharmaceuticals Falls After Wider-Than-Expected 1Q Loss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nARS Pharmaceuticals Falls After Wider-Than-Expected 1Q Loss\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-05-15 00:51</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Chris Wack \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of ARS Pharmaceuticals slipped after the biopharmaceutical company reported a first-quarter loss that was wider than analysts had expected. \n</p>\n<p>\n  The stock was down 9%, to $12.12, in midday trading Wednesday, but has gained about 14% since the start of the year. \n</p>\n<p>\n  The San Diego company reported a first-quarter loss of $34.1 million, or 35 cents a share. Analysts polled by FactSet were looking for a loss of $31.2 million, or 34 cents a share. \n</p>\n<p>\n  Revenue for the quarter was $8 million, compared with the $7.5 million analysts were expecting. \n</p>\n<p>\n  Product revenue from its neffy sales in the U.S. were $7.8 million, and $200,000 in revenue came from a collaboration with Denmark's ALK-Abello. Neffy is a nasal spray used for emergency treatment of allergic reactions, including anaphylaxis. \n</p>\n<p>\n  ARS said it had cash, cash equivalents and short-term investments of $275.7 million as of March 31. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Chris Wack at chris.wack@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 14, 2025 12:51 ET (16:51 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2535008648","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2535008648","pubTimestamp":1747241460,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of ARS Pharmaceuticals slipped after the biopharmaceutical company reported a first-quarter loss that was wider than analysts had expected.The stock was down 9%, to $12.12, in midday trading Wednesday, but has gained about 14% since the start of the year.The San Diego company reported a first-quarter loss of $34.1 million, or 35 cents a share. Analysts polled by FactSet were looking for a loss of $31.2 million, or 34 cents a share.Revenue for the quarter was $8 million, compared with the $7.5 million analysts were expecting.Product revenue from its neffy sales in the U.S. were $7.8 million, and $200,000 in revenue came from a collaboration with Denmark's ALK-Abello. Neffy is a nasal spray used for emergency treatment of allergic reactions, including anaphylaxis.ARS said it had cash, cash equivalents and short-term investments of $275.7 million as of March 31.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","SPRY":"ARS PHARMACEUTICALS INC"},"translate_title":"ARS Pharmaceuticals第一季度亏损超出预期后股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SPRY":0.9},"content_text":"By Chris Wack \n\n\n \n\n\n  Shares of ARS Pharmaceuticals slipped after the biopharmaceutical company reported a first-quarter loss that was wider than analysts had expected. \n\n\n  The stock was down 9%, to $12.12, in midday trading Wednesday, but has gained about 14% since the start of the year. \n\n\n  The San Diego company reported a first-quarter loss of $34.1 million, or 35 cents a share. Analysts polled by FactSet were looking for a loss of $31.2 million, or 34 cents a share. \n\n\n  Revenue for the quarter was $8 million, compared with the $7.5 million analysts were expecting. \n\n\n  Product revenue from its neffy sales in the U.S. were $7.8 million, and $200,000 in revenue came from a collaboration with Denmark's ALK-Abello. Neffy is a nasal spray used for emergency treatment of allergic reactions, including anaphylaxis. \n\n\n  ARS said it had cash, cash equivalents and short-term investments of $275.7 million as of March 31. \n\n\n \n\n\n  Write to Chris Wack at chris.wack@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 14, 2025 12:51 ET (16:51 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}